H.C. Wainwright downgraded 89bio (ETNB) to Neutral from Buy with a price target of $14.50, down from $32, after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: